Cardiomyopathy caused by antineoplastic therapies
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The goals of care for patients at risk for cardiomyopathy induced by cancer treatment should include prevention, early diagnosis, treatment of subclinical cardiac dysfunction, prevention of disease progression, and prolongation of patient survival. Any strategy aimed to minimize the cardiotoxic effects of cancer treatment should maintain the treatment’s antineoplastic efficacy. Successful therapy achieves the highest health-related quality of life that is defined by the balance between maximizing the efficacy of oncologic therapy and minimizing the toxicity of this therapy. Doxorubicin-induced cardiotoxicity can be reduced by limiting the overall cumulative dose.
There is no specific treatment for cancer therapy-related cardiomyopathy, and symptomatic patients should receive standard treatments for congestive heart failure such as afterload reduction, beta-blockers, diuresis, and digoxin. Afterload reduction with angiotensin-converting enzyme inhibitors such as enalapril and captopril may be indicated in patients with elevated afterload and asymptomatic left ventricular dysfunction diagnosed by echocardiography. Beta-blockers may improve myocardial systolic dysfunction and may be useful in the treatment of cancer treatment-induced cardiomyopathy.
Cardiac transplantation remains a viable option in patients with cancer treatment-induced end-stage heart disease.
- Frishman WH, Sung HM, Yee HCM, et al.: Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cardiol 1996, 21:225–286.
- Stone RM, Bridges KR, Libby P: Hematological-oncological disorders and cardiovascular disease. In Heart Disease, edn 6. Edited by Braunwald E, Zipes DP, Libby P, et al. Philadelphia: WB Saunders Co; 2001:2223–2243.
- Giantris A, Abdurrahman L, Hinkle A, et al.: Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998, 27:53–68. A comprehensive review of anthracycline cardiotoxicity.
- Von Hoff DD, Layard MW, Basa P, et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710–717.
- Lipshultz SE, Colan SD, Gelber RD, et al.: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324:808–815. CrossRef
- Liphshultz SE, Lipsitz S, Goorin AM, et al.: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995, 332:1738–1743. CrossRef
- Krischer JP, Epstein S, Cuthbertson DD, et al.: Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience. J Clin Oncol 1997, 15:1544–1552.
- Nysom K, Holm K, Lipsitz SR, et al.: The relation between cumulative anthracylcine dose and late cardiotoxicity in survivors of childhood leukemia. J Clin Oncol 1998, 16:545–550.
- Grenier MA, Lipshultz SE: Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998, 25(suppl 10):72–85.
- Lipshultz SE, Sanders SP, Goorin A, et al.: Monitoring for anthracycline cardiotoxicity. Pediatrics 1994 93:433–437.
- Ensley JF, Patel B, Kloner R, et al.: The clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs 1989, 7:101–109. CrossRef
- Willemze R, Zwaan FE, Colpin G, et al.: High dose cytosine arabinoside in the management of refractory acute leukaemia. Scand J Haematol 1982, 29:141–146. CrossRef
- Vaickus L, Letendre L: Pericarditis induced by highdose cytarabine therapy. Arch Intern Med 1984, 144:1868–1869. CrossRef
- Rowinsky EK, Gilbert MR, McGuire WP, et al.: Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991, 9:1692–1703.
- Rowinsky EK, McGuire WP, Guarnieri T, et al.: Cardiac disturbances during the administration of taxol. J Clin Oncol 1991, 9:1704–1712.
- Arbuck SG, Strauss H, Rowinsky E, et al.: A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 1993, 15:117–30.
- Feldman AM, Lorell BH, Reis SE: Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 2000, 102:272–274. Important review of potential mechanisms of trastuzumab cardiotoxicity.
- Adams MJ, Constine LS, Lipshultz SE: Radiation. In Cardiology. Edited by Crawford MH, Dimarco JP. London: Mosby International Ltd; 2001:15.1–15.8. This chapter provides a comprehensive review of radiation associated heart disease, including pathology, clinical presentation, screening, and treatment.
- Aisenberg AC: Problems in Hodgkin’s disease management. Blood 1999, 93:761–779.
- Totterman KJ, Pesonen E, Siltanen P: Radiation related chronic heart disease. Chest 1983, 83:875–878.
- Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 1993, 11:1208–1215. An important study of late cardiac effects of mediastinal irradiation.
- Billingham ME, Bristow MR, Glatstein E, et al.: Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1977, 1:17–23. CrossRef
- Pihkala J, Saarinen UM, Lundstrom U, et al.: Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 1996, 32:97–103. CrossRef
- Stewart JR, Fajardo LF, Gillette SM, et al.: Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995, 31:1205–1211. CrossRef
- Heart Failure Guideline Panel: Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. Clinical Practice Guideline No 11. Rockville, MD: US Department of Health and Human Services, Agency for Health Care Policy and Research; 1994: AHCPR Publication 94:6012.
- Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995, 92:2764–2784.
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
- Hensley ML, Schucter LM, Lindley C, et al.: American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999, 17:3333–3355.
- Lipshultz SE: Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 1996, 14:328–331.
- Lipshultz SE, Rifai N, Sallan SE, et al.: Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997, 96:2641–2648.
- Herman EH, Zhang J, Lipshultz SE, et al.: Correlation between serum levels of cardiac troponin-T and the severity of chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999, 17:2237–2243.
- Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Eng J Med 1992, 327:669–677. CrossRef
- MICROMEDEX Healthcare Series, vol 109 [online database]. URL: http://mdx.com. Accessed June 27, 2001.
- Drug Topics Red Book. Montvale, NJ: Medical Economics Co; 2001.
- Noori A, Lindenfeld J, Wolfel E, et al.: Beta-blockade in adriamycin-induced cardiomyopathy. J Cardiac Fail 2000, 6:115–119.
- Dillon TA, Sullivan M, Schatzlein MH, et al.: Cardiac transplantation in patients with preexisting malignancies. Transplantation 1991, 52:82–85. CrossRef
- Stevenson LW, Warner SL, Steimle AE, et al.: The impending crisis awaiting cardiac transplantation. Modeling a solution based on selection. Circulation 1994, 89:450–457.
- Li T, Singal PK: Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 2000, 102:2105–2110.
- Cascinu S, Cordella L, Del Ferro E, et al.: Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995, 13:26–32.
- De Maria D, Falchi AM, Venturino P: Adjuvant radiotherapy of the pelvis with or without reduced glutathione: a randomized trial of in patients operated on for endometrial cancer. Tumori 1992, 78:374–376.
- Jain KK, Casper ES, Geller NL, et al.: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985, 3:818–826.
- Cottin Y, Touzery C, Dalloz F, et al.: Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol 1998, 21:665–670. CrossRef
- Anderlini P, Benjamin RS, Wong FC, et al.: Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995, 13:2827–2834.
- Cardiomyopathy caused by antineoplastic therapies
Current Treatment Options in Cardiovascular Medicine
Volume 3, Issue 6 , pp 493-505
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Divisions of Cardiology and Gastroenterology/Nutrition, Department of Pediatrics, and Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 631, 14642, Rochester, NY, USA